Table 1 Patient Self-Reported Demographic and Clinical Characteristics
Characteristic | Results |
|---|---|
Total Number | 105 |
Female, % (N) | 79% (83) |
Age, Years, Mean ± SD | 50 ± 12.5 |
Duration of Acromegaly, Years, Mean ± SD | 10 ± 8.1 |
Current SRL, % (N) | |
Octreotide (n = 42) | 40% (42) |
Low dose (< 20 mg total/month) | 29% (12) |
Middle dose (20 mg to < 30 mg total/month) | 38% (16) |
High dose (≥ 30 mg total/month) | 33% (14) |
Lanreotide (n = 63) | 60% (63) |
Low dose (< 90 mg total/month) | 24% (15) |
Middle dose (90 mg to < 120 mg total/month) | 38% (24) |
High dose (≥120 mg total/month) | 38% (24) |
Procedure, % (N) | |
Pituitary surgery only | 61% (64) |
Both pituitary surgery and radiotherapy | 30% (31) |
Neither pituitary surgery or radiotherapy | 10% (10) |
Time Since Last Surgery, Years, Mean ± SD (n = 95) | 9 ± 7.3 |
Time Since Last Radiotherapy, Years, Mean ± SD (n = 31) | 9 ± 7.9 |
Medications for Acromegaly, % (N) | |
SRL Only | 63% (66) |
SRL + Pegvisomant | 17% (18) |
SRL + Cabergoline | 11% (11) |
SRL + Pegvisomant + Cabergoline | 5% (5) |
Unknown | 4% (4) |
Self-perception of symptom control, % (N) | |
Well controlled | 29% (30) |
Partially controlled | 48% (50) |
Not controlled | 22% (22) |
Not sure | 3% (3) |
IGF-1, ULN, Mean ± SD (n = 47) | 0.85 ± 0.56 |
IGF-1 < = 1 ULN | 79% (37) |
IGF-1 > 1 ULN | 21% (10) |
Self-perception of biochemical control | |
Well controlled | 66% (69) |
Partially controlled | 26% (27) |
Not controlled | 5% (5) |
Not sure | 4% (4) |